Patient Recruitment/Retention Featured Articles

  1. The Problem With Excluding Children From GLP-1 Trials In The U.S. 2/19/2026

    In the U.S., roughly 15 million children are obese. But many are excluded from GLP-1 research. Obesity expert Evan Nadler, MD, explains why that's problematic.

  2. How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial Workflows 2/17/2026

    Learn how AI-enabled personal health technologies are impacting key aspects of trial operations while also exploring operational challenges that clinical operations leaders must manage in this AI-driven era.

  3. 4 Steps For Representative Enrollment In Rare Disease Trials 2/16/2026

    Discover the D.A.T.A. method and its utility in enrolling diverse representative patient populations in rare disease clinical trials.

  4. Heard At SCOPE: Pharma Wants ROI For Patient Data Return, Diverse Enrollment 2/11/2026

    Twice I heard “ROI is the elephant in the room.” Two different panel discussions, two different tracks. 

  5. The FDA Calls For Culturally-Informed Research, But What Do We Understand About The Sikh Community? 2/9/2026

    Despite the size and visibility of the community — and the call for diverse patient research — there remains a gap in available health data specific to the Sikh community in the U.S.

  6. The Key Role Of Clinical Supply Teams In Patient Centricity Efforts 2/9/2026

    Clinical supply decisions shape patient access, safety, and trial success. From logistics to procurement, patient-centric supply can accelerate therapies or quietly delay them.

  7. Building Patient Trust In Research Through Connection Driven-Transparency 2/4/2026

    The question is not whether trust matters but how industry, sponsors, and investigators can bridge the trust gap to drive patient participation.

  8. Patient Trust In Pharma Is Low; Here's How To Rebuild It 2/2/2026

    CISCRP's Annick de Bruin and Shalome Sine provide strategies for building patient trust based on the findings from their Perceptions & Insights Study.

  9. How Gilead Includes Patients Most Affected By HIV In Its PrEP Trials 1/26/2026

    VP of Clinical Development, HIV, Moupali Das shares how the sponsor approaches diverse participant recruitment and enrollment, highlighting the importance of early demographic research and careful, intentional PI selection.

  10. Confronting "Time Toxicity" In Global Oncology And Rare Disease Trials For Operational Excellence And Patient Retention 1/14/2026

    Time is the only truly finite resource in a clinical trial. Consultant Leila Cupersmith discusses how sponsors can better design trials with a lower time burden to boost enrollment, retention, and overall operational excellence.